Exosome-mediated X‑chromosome dosage transfer as a conserved mechanism of mammalian longevity

Hypothesis

We propose that exosomes secreted by XX cells preferentially package X‑linked escape transcripts and proteins, and that this intercellular transfer compensates for the haploid X dosage in XY tissues, thereby extending lifespan. When exosomal transfer is inhibited, the XX longevity advantage diminishes; augmenting exosomal delivery of X‑derived factors to XY animals rescues age‑related decline.

Rationale

• Across mammals, XX individuals live longer than XY counterparts independent of gonadal hormones ([1],[2]).
• Centenarian females show balanced X‑chromosome inactivation, whereas skewed inactivation correlates with aging ([3]).
• Loss of the Y chromosome in aging male immune cells triggers compensatory upregulation of X‑linked escape genes such as DDX3X, KDM5A, KDM5C, ZRSR ([4]).
• No published data test whether exosomes preferentially carry X‑chromosome cargo or whether such cargo influences longevity outcomes.

We hypothesize that RNA‑binding proteins encoded by X‑linked escape genes (e.g., KDM5C) recognize specific X‑transcripts and load them into exosomes via the ESCRT pathway. These exosomal RNAs and proteins then modulate stress‑response, DNA‑repair, and proteostasis networks in recipient cells, effectively providing a trans‑cellular dosage compensation mechanism.

Experimental Plan

1. Exosome isolation and profiling

   • Collect exosomes from primary fibroblasts of XX and XY mice (young and old).
   • Perform small‑RNA‑seq and proteomics to quantify X‑linked escape transcripts (DDX3X, KDM5A, KDM5C, ZRSR) and proteins.
   • Expect enrichment of X‑derived cargo in XX exosomes relative to XY (testable by fold‑change >2, p<0.01).

2. Functional inhibition

   • Treat XX mice with GW4869 (neutral sphingomyelinase inhibitor) to block exosome release from middle age onward.
   • Monitor lifespan, frailty index, and tissue‑specific markers of aging (p16^INK4a, γH2AX).
   • Prediction: GW4869‑treated XX mice will show a significant reduction in lifespan advantage over untreated XY controls (effect size ~10% of XX benefit).

3. Gain‑of‑function rescue

   • Purify XX‑derived exosomes and inject them intravenously into aged XY mice monthly.
   • Assess healthspan metrics (grip strength, glucose tolerance) and survival.
   • Prediction: Exosome‑treated XY mice will exhibit extended median lifespan comparable to XX littermates, accompanied by increased expression of X‑escape target genes in somatic tissues.

4. Genetic validation

   • Generate conditional knockout of KDM5C in XX hematopoietic cells to disrupt its putative role in exosomal sorting.
   • Evaluate exosome cargo composition and recipient cell signaling.
   • Prediction: Loss of KDM5C will diminish X‑linked transcript loading into exosomes and abrogate the protective effect of XX exosomes on XY recipients.

Potential Outcomes and Interpretation

• Supported: Consistent enrichment of X‑linked escape molecules in XX exosomes, lifespan shortening upon exosome blockade, and rescue by exogenous XX exosomes would substantiate the hypothesis that intercellular transfer of X‑chromosome dosage constitutes a conserved longevity mechanism.
• Refuted: Lack of cargo bias, no lifespan alteration after exosome inhibition, or failure of XX exosomes to extend XY lifespan would suggest that the observed sex‑differences in longevity arise from cell‑intrinsic dosage effects rather than exosomalmediated transfer.

This framework directly links X‑chromosome biology to intercellular communication, offering a testable route to resolve whether the “longevity chromosome” acts through secreted vesicles that balance genomic dosage across sexes.